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Stroke is a rare disease in children, with an estimated incidence 13/100000 and a signiﬁcant impact on morbidity and mortality.
Clinical presentation and risk factors, present in almost half of pediatric patients, are not the same as in adults. The diagnosis of
stroke in children is often delayed because signs and symptoms can be subtle and nonspeciﬁc. History and clinical examination
should exclude underlying diseases or predisposing factors. Neuroimaging is crucial in deﬁning diagnosis. Other tests might be
necessary, according to the clinical picture. We present here the most recent practical directions on how to diagnose and manage
arterial stroke in children, according to diﬀerent international guidelines on the subject.
1.Introduction
The World Health Organization (WHO) deﬁnes stroke as
“a clinical syndrome of rapidly developing focal or global
disturbance of brain function lasting >24 hours or leading
to death with no obvious nonvascular cause” [1]. This deﬁ-
nition should be integrated by a reference to neuroimaging,
at present considered essential to deﬁne the neurovascular
origin of symptoms. A modern deﬁnition could be “a clini-
cal syndrome characterized by (1) a neurological deﬁcit rela-
ted to the perfusion territory of a cerebral artery and (2)
neuroradiological evidence of an ischemic lesion” [2, 3].
Transient ischemic attacks (TIAs) are deﬁned as “a
sudden, focal neurologic deﬁcit that lasts for less than 24
hours,ofpresumedvascularorigin,conﬁnedtoanareaofthe
brain or eye perfused by a speciﬁc artery” [4]. In childhood,
on the contrary, even in the presence of transient symptoms,
imaging often shows a cerebral infarction [5].
Strokes are classically divided in primarily ischemic or
hemorrhagic. While adult strokes are prevalently ischemic
(80%) and due to atherosclerosis, in childhood up to 45%
of strokes are hemorrhagic and are associated with a wide
spectrum of risk factors [6].
The estimated incidence of ischemic stroke in children
o l d e rt h a n2 8d a y so fl i f ei sv a r i a b l e[ 7–9] but, according to
a large prospective, population study, it averages 13/100.000
for all strokes, 7.9/100.000 for ischemic strokes, and 5.1 for
hemorrhagic strokes [8]. Approximately 20% of children
die after an ischemic stroke while more than 50% of those
surviving present neurological sequelae, most commonly
hemiparesis [7, 9] .T h ec u m u l a t i v es tr o k er e c u rr e n c era t eh a s
been reported to be 15% at 1 year, and 19% at 5 years [10],
a n du pt o4 1 %a t5y e a r s[ 11].
A risk factor is present in almost half of the children at
the time of stroke [12]( Table 1). Common risk factors in
childhood are congenital heart disease, sickle cell disease,
infections, and various prothrombotic conditions [13–15].
The most common cause of stroke in children is probably
heart disease, detected in 19% of children with arterial
thrombosis (Canadian Pediatric Ischemic Stroke Registry)
[16]. Recent studies underline the importance of infection:
it seems that at least a third of cases of childhood stroke
occur in such a context. A ﬁfth of the children with
ischemic infarction of unknown origin has a history of prior
chickenpox [16–18].
In about 80% of children with arterial stroke, arterial
imaging is abnormal [12].
The purpose of this paper is to provide practical up-
to-date directions on how to diagnose and manage arterial
stroke in children (1 month–18 years), in an emergency
department. Neonatal stroke is not included because of its
peculiar characteristics.2 Stroke Research and Treatment
Table 1: Risk factors for pediatric stroke.
Congenital heart disease
Ventricular/atrial septal defect
Patent ductus arteriosus
Aortic/mitral stenosis
Coarctation
Cardiac rhabdomyoma
Complex congenital heart defects
Acquired heart disease
Rheumatic heart disease
Prosthetic heart valve
Endocarditis
Cardiomyopathy
Myocarditis
Atrial myxoma
Arrhythmia
Systemic vascular disease
Systemic hypertension
Volume depletion or systemic hypotension
Hypernatremia
Superior vena cava syndrome
Diabetes
Vasculitis
Meningitis
Systemic infection
Systemic lupus erythematosus
Polyarteritis nodosa
Granulomatous angiitis
Takayasu’s arteritis
Rheumatoid arthritis
Dermatomyositis
Inﬂammatory bowel disease
Drug abuse (cocaine, amphetamines)
Hemolytic-uremic syndrome
Vasculopathies
Ehlers-Danlos syndrome
Homocystinuria
Moyamoya syndrome
Fabry’s disease
Malignant atrophic papulosis
Pseudoxanthoma elasticurn
NADH-CoQ reductase deﬁciency
Vasospastic disorders
Migraine
Ergot poisoning
Vasospasm with subarachnoid hemorrhage
Hematologic disorders and coagulopathies
Hemoglobinopathies (sickle cell anemia, sickle
cell-hemoglobin C, sickle-thalassemia)
Immune thrombocytopenic purpura
Thrombotic thrombocytopenic purpura
Table 1: Continued.
Hematologic disorders and coagulopathies
Thrombocytosis
Polycythemia
Disseminated intravascular coagulation
Leukemia or other neoplasms
Congenital coagulation defects
Oral contraceptive use
Antithrombin III deﬁciency
Protein S deﬁciency
Protein C deﬁciency
Congenital serum C2 deﬁciency
Liver dysfunction with coagulation defect
Vitamin K deﬁciency
Lupus anticoagulant
Anticardiolipin antibodies
Structural anomalies of the cerebrovascular system
Arterial ﬁbromuscular dysplasia
Agenesis or hypoplasia of the internal carotid or
vertebral arteries
Arteriovenous malformation
Hereditary hemorrhagic telangiectasia
Sturge-Weber syndrome
Intracranial aneurysm
Trauma
Child abuse
Fat or air embolism
Foreign body embolism
Carotid ligation
Vertebral occlusion following abrupt cervical rotation
Posttraumatic arterial dissection
Blunt cervical arterial trauma
Arteriography
Posttraumatic carotid cavernous ﬁstula
Coagulation defect with minor trauma
Penetrating intracranial trauma
In preparing this work we followed the most recent
guidelines on arterial stroke in childhood (Pediatric Stroke
WorkingGroup,2004;AmericanCollegeofChestPhysicians,
2004; Italian Society of Pediatrics, 2007; American Stroke
Association, 2008).
Additionally, a literature review was made, analyzing rel-
evant articles on the subject, up to August, 2010 by searching
Pubmed, EMBASE, Cochrane Library and in bibliographies
of relevant articles. Search terms were “stroke,” “emergency,”
“child,” “childhood,” “management.”
2.Diagnosis
2.1. Clinical Presentation. The clinical presentation of stroke
diﬀers depending on age, involved artery, and cause [19, 20].Stroke Research and Treatment 3
Table 2: Clinical presentation of stroke depending on the involved
artery.
Vascular territory Symptoms
Internal carotid artery Hemiparesis, aphasia, and hemianopsia
Anterior cerebral artery Hemiparesis, especially leg
Middle cerebral artery Arm hemiparesis, hemianopsia, and
aphasia
Posterior cerebral artery Hemianopsia, ataxia, hemiparesis, and
dizziness
Basilar artery
Breath, sensory or balance disturbances,
ataxia, nystagmus, opisthotonus,
tremor, and vomiting
Cerebellar artery Sensory disturbances, headache, fever,
vomit, and cerebellar signs
While in infancy symptoms are usually aspeciﬁc, in older
children, the most frequent presenting symptoms are focal
neurologic deﬁcits such as hemiplegia or a gross, focal motor
deﬁcit [21].
Symptoms according to the involved artery are listed in
Table 2. The vascular territory of the middle cerebral artery
is the most frequently aﬀected.
2.2. Diﬀerential Diagnosis. Diagnosis of stroke in children is
often delayed because signs and symptoms can be subtle and
nonspeciﬁc, such as mild single limb weakness, incoordina-
tion, and sensory disturbances, initially attributed to causes
other than stroke [22].
In a child presenting with an acute neurologic deﬁcit,
before a diagnosis of ischemic stroke is made, other cere-
brovascular diseases (hemorrhagic stroke, cerebral venous
sinus thrombosis) need to be considered.
Frequent causes of acute hemiplegia are Todd’s palsy,
where focal seizures usually precede monoparesis or hemi-
plegia, and hemiplegic migraine, in which hemiplegia is
preceded by visual or sensitive disorders and followed by
headache. It is also necessary to exclude meningoencephali-
tis, generally associated with fever, headache and altered
consciousness.
Acute neurologic deﬁcits may be caused by tumors, cen-
tral nervous system disorders including acute disseminated
leukoencephalitis, cerebellitis, reversible posterior leukoen-
cephalopathy, alternating hemiplegia, metabolic disorders,
epilepsy, and psychogenic diseases [23].
2.3. Early Investigations (on Presentation). The ﬁrst step to
detect a stroke is including this option in the diﬀerential
diagnosis of an acutely ill child. Early diagnosis allows
prompt starting of appropriate therapy.
2.3.1. History. Clinical history should include ethnic origin,
the presence of sickle cell disease or congenital heart
disease, head or neck trauma (associated with intracranial
hemorrhage and dissection), recent infection (especially
chickenpox), vasculitis and blood disorders [19], as well as
cerebrovascular diseases, coagulopathies, or immunologic
disorders among ﬁrst-degree relatives.
How and how rapidly symptoms develop is of major
importance. Up to a third of children who have had a stroke
have a history of recent events consistent with TIAs [24].
2.3.2. Physical Examination. A complete physical and neuro-
logic examination, including monitoring of vital parameters,
will identify neurologic damages and allow presumptive
diagnosis of the brain vessel involved. Signs of systemic
diseases that increase the risk of stroke should be looked for.
2.3.3. Imaging Studies. Non-contrast computed tomography
(CT) can be performed promptly and quickly in emergency.
It can adequately exclude hemorrhagic stroke or parenchy-
mal abnormalities that produces a mass eﬀect, and it may
reveal a low-density lesion in arterial ischemic stroke and
cerebral venous sinus thrombosis. However, CT is usually
normal within the ﬁrst 12 hours after the onset of symptoms
[6]. It should be requested whenever magnetic resonance
(MR) is not available [19].
MR, in fact, is the “gold standard” imaging modality for
the investigation of arterial ischemic stroke in infants and
children [25] due to its greater sensitivity and speciﬁcity. MR
is useful to diﬀerentiate stroke from “stroke mimics” but it is
rarely available in emergency [26]. The diagnostic eﬃciency
of MR can be further improved by perfusion techniques,
thatquantifyrelativecerebralbloodﬂow,volume,andtransit
time by the use of bolus administration of gadolinium-based
contrast material [5, 27, 28].
MR with diﬀusion weighting is very useful in accurately
identifying regions of early ischemia and infarction [26]. MR
angiography is a noninvasive procedure that detects large
vascular abnormalities [29] ,a n di ti sa se ﬀective as cerebral
angiography in identifying large ischemic lesions [30]. MR
angiography is a reasonable alternative to conventional
arteriographyinmostpatients[31,32].Ifthepatternofbrain
injurycouldbeconsistentwithvenousinfarction,emergency
vascular imaging should include MR venography. In fact,
10% of hemorrhagic strokes in children are secondary to
cerebral venous sinus thrombosis [6].
Vascular imaging of the extracranial circulation, such as
cervical MRA or Doppler ultrasound, should also be per-
formed, particularly if the history is suggestive of a cervical
arterial dissection.
2.3.4. Other Investigations. Complete blood cell count, iron
studies, prothrombin time, partial thromboplastin time,
sedimentation rate, and antinuclear antibodies could be
useful [19].
2.4. Second-Line Investigations (after 48 Hours as Indicated).
Once stroke has been diagnosed, several studies may be
helpful for the ongoing evaluation and management of the
patient.
Electrocardiogram and transthoracic or transesophageal
echocardiogram are always necessary in all children with
known or suspected congenital heart disease who have had
as t r o k e[ 20, 33].
Echocardiography may be helpful to diagnose patent
foramen ovale; this abnormality can be up to four times4 Stroke Research and Treatment
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Figure 1: Flowchart: diagnosis of ischemic stroke in emergency.
greater in children with stroke with undetermined etiology
than in the general population [34].
The diagnosis of some conditions, including extracra-
nial arterial dissection, particularly involving the posterior
circulation, and small-vessel vasculitis, is diﬃcult using MR
angiography alone. In these circumstances, catheter cerebral
angiography is sometimes required. However, catheter cere-
bral angiography is an invasive procedure, not commonly
performed in children, and it has similar diagnostic yield as
MR combined with MR venography and MR arteriography
[6].
Conventional angiography can be necessary in order to
identify moyamoya syndrome [19].
Hemoglobin electrophoresis and urine drug screening,
particularly for sympathomimetics may be indicated. A full
evaluation for thrombophilia is reasonable in all children
with stroke. It should include evaluation of protein C and
protein S deﬁciency, antithrombin III, heparin cofactor II,Stroke Research and Treatment 5
plasminogen, von Willebrand’s antigen, factor VIII, fac-
tor XII, factor V Leiden, activated protein C resistance,
prothrombin 20210 gene, serum homocysteine, methylene-
tetra-hydro-folate-reductase, lipoprotein (a), and antiphos-
pholipid antibodies [35–37]. When indicated on the basis
of clinical suspicion, more extensive diagnostic testing, such
as cerebrospinal ﬂuid analysis, lipid proﬁle, Varicella-Zoster
and human immunodeﬁciency virus, and screening for
metabolic disorders might be performed. However, in the
majority of cases, the results of these studies will not have
an impact on emergency care [19]. We suggest a ﬂow chart
for diagnosis of ischemic stroke in emergency (see Figure 1).
3. Management in Emergency
Guidelines based on strong evidence for the acute care of
childhoodstrokedonotexist,withtheexceptionofsicklecell
disease. Therefore, treatment recommendations for ischemic
stroke in children are extrapolated from adult guidelines.
Children with early acute ischemic cerebral stroke need
to be admitted to a clinical unit where continuous monitor-
ing is possible. Only in selected cases treatment in intensive
care units is needed [38, 39].
3.1. Supportive Care. The general approach in emergency
includes simple measures such as maintenance of respiratory
and cardiovascular functions, aggressive treatment of infec-
tion, seizures and fever, maintenance of normoglycemia and
normovolemia[20,40],andoxygensupplementationtokeep
SaO2 > 95% during the ﬁrst 24 hours after stroke [41]. Med-
ical or surgical treatment of intracranial hypertension, when
present, is important, because children have higher risk of
tonsillar herniation due to cerebral edema. Hyperventilation
is a short term solution that should be used for imminent
herniation until a deﬁnitive therapy, such as decompressive
neurosurgery, can be oﬀered [40, 42, 43].
3.2. Anticoagulant Therapy and Antiplatelet Agents. The
choice between anticoagulant and antiplatelet agents is
controversial and there are few data to guide this decision in
children [44].
As anticoagulation therapy, both unfractionated heparin
and low molecular weight heparin (LMWH) have been
used in children with AIS. Current guidelines recommend
anticoagulation in children with proven arterial dissection
or cardioembolic stroke or during the diagnostic evaluation
period, until a cardiac source or an arterial dissection has
been excluded [42]. Heparin should be used in children
thought to have a high risk of recurrence and a low risk of
secondary hemorrhage [5, 45].
According to the international literature, LMWH at the
dose of 1mg/kg every 12 hours represents a safe initial ther-
apy for ischemic stroke in infants and children. Hemorrhagic
stroke needs to be excluded before starting treatment [46–
49]. Low molecular weight heparin oﬀers several advantages
over standard unfractionated heparin and oral anticoag-
ulants: lower risk of heparin-induced thrombocytopenia,
fewer drug interactions, fewer adverse eﬀects on bone when
given long term, and lower cost. Furthermore, LMWH
is administered subcutaneously, and it demonstrates pre-
dictable age-dependent pharmacokinetics and less need for
monitoring, thus reducing the need for multiple venipunc-
tures [46]. Enoxaparin (1mg/kg subcutaneously for children
more than 2 months of age, or 1.5mg/kg for infant less than
2 months of age) is the most frequently used LMWH in
children [47]. In children with cardiac embolism or vascular
dissection, LMWH is administered for 3 to 6 months [50].
Concerning antiplatelets, even in absence of randomized
clinical trials for the use of aspirin in the acute treatment
of AIS in children, most experts agree that this drug use is
reasonable for secondary stroke prevention. Standard dosage
of 1 to 5mg/kg/day for a minimum of 3 to 5 years from the
acute event is recommended as secondary prevention [50].
The increased risk of Reye’s syndrome should be considered.
Clopidogrel has been used at dosages of about 1 mg/kg per
day in children unable to take aspirin [42, 51].
Thrombolysis with tissue plasminogen activator (tPA) is
not currently used and the Royal College of Physicians, AHA
Stroke Council, and ACCP guidelines do not recommend
it. In fact, the diagnosis of stroke in children is usually
made after the time interval required for intravenous or
intraarterial tPA thrombolysis (3 hours and 6 hours after
stroke onset, resp.) [3, 52–54].
The International Paediatric Stroke Study group recom-
mends that thrombolysis should not be used unless it is part
of randomised control trial [55, 56].
4. HemorrhagicStroke
Hemorrhagic stroke is as common as arterial ischemic stroke
with an estimated incidence of 1.5–2.9 per 100.000 children
p e ry e a r[ 41]. It includes spontaneous intraparenchymal
hemorrhage and nontraumatic subarachnoid hemorrhage.
Structural lesions are the most common causes of intra-
parenchymal hemorrhages in a population-based cohort
[57]. Brain tumors (27%) and arteriovenous malformations
(17%) are the most frequent. Medical etiologies are less
common. Coagulopathies (13%) include various causes
of thrombocytopenia, hemophilia and von Willebrand’s
disease, sickle cell anemia (6%), hypertension (10%), and
infections (6%). Intraparenchymal hemorrhages of idio-
pathic origin are also frequent (23%).
Non-traumatic subarachnoid hemorrhages are most
often caused by intracranial aneurysms. Ruptured aneurys-
ms account for 10% of intracranial hemorrhages in children.
The incidence of subarachnoid hemorrhage is increased in
variouscongenitalandhereditaryconditionssuchascerebral
artero-venous malformations, cardiac disorders (coarctation
of the aorta, bacterial endocarditis, and atrial myxoma),
autosomal dominant polycystic kidney disease, connective
tissueabnormalities(Marfan’ssyndrome,ﬁbromusculardys-
plasia, and Ehlers-Danlos type IV), hematological disorders
(sickle cell disease, G6PD deﬁciency, and thalassemia),
phakomatoses (neuroﬁbromatosis type 1, especially follow-
ing radiation therapy and tuberous sclerosis) [58].
Headacheorvomitingduetoraisedintracranialpressure,
seizures and focal neurologic deﬁcits are the presenting
symptoms in children [41]. During evaluation of pediatric6 Stroke Research and Treatment
Table 3: Risk factors for stroke in sickle cell disease.
(i) high blood ﬂow velocity on transcranial Doppler
(ii) low hemoglobin value
(iii) high HbS level
(iv) high white cell and platelet counts
(v) hypertension
(vi) silent brain infarction
(vii) history of chest crisis, transient ischemic attacks, menin-
gitis, seizures, surgery, priapism, acute anemia, and transfusion
within 2 weeks before the stroke
stroke it is mandatory to exclude an acute intraparenchymal
bleeding. To this end non-contrast TC should be performed.
Treatment of hemorrhagic stroke requires a multidisci-
plinary team management with neurological and neurosur-
gical care.
Management options in hemorrhagic stroke fall into
two categories: general eﬀorts to stabilize the patient and
measures to reduce the risk of rebleeding [5].
Surgical management is controversial, and there is no
evidence that surgical evacuation of a supratentorial intra-
parenchymal hematoma is beneﬁcial at any age [59, 60].
However, evacuation of a rapidly expanding hematoma
causing cerebral herniation may be of beneﬁt [6]. Surgical
or endovascular obliteration of aneurysms and artero-
venous malformations is eﬀective for many individuals,
but stereotactic radiotherapy is being used increasingly in
children with artero-venous malformations that are small
or diﬃcult to approach surgically. Several large retrospective
studies have shown that stereotactic radiotherapy is safe and
eﬀective for the treatment of children with an artero-venous
malformation [61, 62].
Treatment of coagulation defects and hematologic dis-
orders should reduce the risk of subsequent hemorrhage.
Emergency splenectomy is indicated for intraparenchymal
bleeding associated with idiopathic thrombocytopenic pur-
pura. Other important complications of non-traumatic
subarachnoid hemorrhage that require treatment are hydro-
cephalus, vasospasm, and hyponatremia [5].
5. Stroke in Sickle CellDisease
Themostcommonhematologicriskfactorforstrokeissickle
cell disease (SCD). Eight percent of patients younger than 19
years will develop a stroke. In this group the highest rate of
ﬁrst ischemic stroke is in children between 2 and 5 years of
age while hemorrhagic stroke aﬀects adults aged 20 to 30
years. Both familial and environmental factors seem to be
involved in the occurrence of stroke [19]. In the absence of
therapy recurrence of stroke is as high as 40% [63].
Small infarctions have been found on MR in 20 to 35%
of children with SCD in the absence of symptoms [64, 65].
These so-called “silent infarcts,” predominantly located in
frontal and parietal cortical, subcortical, and border-zone
areas are associated with deterioration in cognitive function
and with an increased risk of clinically symptomatic stroke
[66, 67].
Stroke may also be due to large vessel vasculopathy
that generally involves the middle cerebral artery territory.
Some individuals develop progressive vasculopathy of the
intracranial internal carotid artery and of its distal collateral
vessels, a picture called moyamoya syndrome. Small infarc-
tions typically involve the basal ganglia and the deep white
matter within the anterior circulation.
Risk factors for stroke in SCD are summarized in Table 3.
5.1. Prevention. T h ep r e s e n c eo fh i g hc e r e b r a lb l o o dﬂ o w
velocity as measured by transcranial Doppler (TD) identiﬁes
patients at high risk of primary prevention.
In healthy children, the velocity in the middle cerebral
artery is around 90cm/s while in SCD children it is 130–
140cm/s. Stroke risk is high when velocity is >200cm/s.
A randomized trial (Stroke Prevention Trial in Sickle Cell
Anemia:STOP) compared periodic blood transfusion with
standard care in 130 children with SCD who were selected
for high stroke risk on the basis of TD results. The trial was
haltedbecauseofthehighnumberofstrokesinthestandard-
care arm compared with the transfusion-treated group (11
versus 1), in whom the risk of stroke was reduced from 10%
to <1 %p e ry e a r[ 68].
The current National Heart, Lung, and Blood Institute of
the National Institutes of Health (NHLBI) recommendation
is to evaluate children between 2 and 16 years with SCD
using TD at 6 month intervals. If velocity is >200cm/s,
conﬁrmed after a control performed few weeks later, chronic
transfusion therapy should be started [63] and should not be
discontinued even if TD normalizes (as demonstrated by the
randomized controlled trial STOP II [5]).
5.2. Therapy. The treatment of acute ischemic infarction
resulting from SCD includes intravenous hydration and
exchange transfusion to keep HbS <30% and Hb between
10–12.5g/dL [69]. Exchange transfusion avoids the theoreti-
cal risk of increasing blood viscosity that could accompany a
rapid increase of the hematocrit [5].
6. Conclusions
Stroke is relatively rare in children, except, as mentioned,
in sickle cell disease. It represents, however, one of the
ten “top causes” of childhood death. Its relatively rarity
causes a lack of awareness that cerebrovascular disease
occurs in children. Furthermore, risk factors and clinical
presentation are distinctive compared to adults. For these
reasons diagnosis is often delayed. It has been estimated
that 48–72 hours frequently elapse between the onset of
symptoms and diagnosis [70].
Whenevaluatingachildwithstroke,severaltests,includ-
ing imaging studies, are helpful to conﬁrm the diagnosis, to
diﬀerentiate hemorrhagic from ischemic stroke, and to guide
the emergency management.
No uniform approach exists for the treatment of child-
hood stroke. Until data based on randomized pediatric
clinical trials will be available, treatment recommendations
f o rt h ea c u t ec a r eo fc h i l d r e nw i t hs t r o k ew i l lc o n t i n u et ob e
extrapolated from adult guidelines.Stroke Research and Treatment 7
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